(Cervicitis)
828,834 results
  • [Dynamic tongue reconstruction with reinnervated free gracilis muscle flap]. [Case Reports]
    Orv Hetil. 2026 Nov 01; 167(44):1785-1789.Füzes A, Szanyi S, … Oberna FOH
  • At our center, free flap reconstruction is the gold standard after subtotal or total glossectomy performed for oncological indications. In microvascular reconstructive surgery, several factors must be considered when selecting a flap. In the absence of a flap that meets all requirements perfectly, we strive to restore the functions that most significantly affect the quality of life. Removal of th…
  • Incidental Thyroid Neuroendocrine Carcinoma Revealing a Presumed Occult Gastrointestinal Malignancy. [Case Reports]
    Cureus. 2026 Oct; 18(10):e117310.Walker RJ, Aly FZ, … Sullivan CAC
  • In rare cases, a thyroid mass may represent metastatic neuroendocrine disease rather than a primary thyroid malignancy. This case report describes a unique presentation of neuroendocrine carcinoma involving the thyroid with concurrent somatostatin receptor-positive gastrointestinal and mesenteric lesions of uncertain origin, providing insight into the diagnostic and management challenges of this …
  • Van Neck-Odelberg Disease in a Pediatric Patient With Prolonged Groin Pain: A Case Report. [Journal Article]
    Case Rep Radiol. 2026; 2026:6687686.Borborah BCR
  • Van Neck-Odelberg disease is a benign disorder of the ischiopubic synchondrosis (IPS) that can be mistaken for infection, fracture, or bone tumor. A boy aged 10 years and 7 months presented with a 1-year history of exertional groin pain and intermittent limping. The pain was bilateral but consistently worse on the right and was aggravated by football and running. He was afebrile. Examination show…
  • PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026. [Letter]
    J Hematol Oncol. 2026 Oct 31; 19(1).Wang Z, Guo C, … Chen ZJH
  • PD-(L)1×VEGF bispecific antibodies integrate immune checkpoint blockade and VEGF inhibition within a single molecule, offering a potential strategy to overcome angiogenesis-associated immune resistance. At the 2026 ASCO Annual Meeting, the randomized phase 3 HARMONi-6 trial demonstrated an overall survival benefit with ivonescimab plus chemotherapy over tislelizumab plus chemotherapy in previousl…